QuickView for c-MYC;jsessionid=5D314ADDB3AC28D40A92492569460247;jsessionid=109E3114723493C0B3856284D03206C3;jsessionid=E900AC2E5CD08E25CA13763326E60116;jsessionid=4FCC01A74D543F5A337805EAC01FFB48;jsessionid=4D90CE077EE371D25072101DF3D08681 (gene)

1. Survey of activation-induced genome architecture reveals a novel enhancer of Myc.
2. Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma.
3. Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target i…
4. MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding site…
5. Therapeutic targeting of "undruggable" MYC.

There were no clinical trials for c-MYC;jsessionid=5D314ADDB3AC28D40A92492569460247;jsessionid=109E3114723493C0B3856284D03206C3;jsessionid=E900AC2E5CD08E25CA13763326E60116;jsessionid=4FCC01A74D543F5A337805EAC01FFB48;jsessionid=4D90CE077EE371D25072101DF3D08681